<DOC>
	<DOCNO>NCT02511340</DOCNO>
	<brief_summary>Multi-center , single stage , phase II study evaluate efficacy safety Flumatinib accelerate blastic Phase chronic myelogenous leukemia patient .</brief_summary>
	<brief_title>A Phase II Study Evaluate Efficacy Safety Flumatinib CML-AP CML-BP Patients</brief_title>
	<detailed_description>Multi-center , single-arm , open-label , phase II study investigate efficacy safety Flumatinib Chinese patient accelerate blastic Phase chronic myelogenous leukemia . The start daily oral dose Flumatinib 600mgï¼Œcore test six cycle ( cycle 28 day ) , collect core test data primary efficacy analysis . The long treatment time 12 cycle .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Blast Crisis</mesh_term>
	<criteria>Male female patient age 1875 yearold ; ECOG 0 2 ; Newly diagnose previously treat Ph+ CML patient accelerate blastic Phase ; Adequate organ function ; Written inform consent prior study procedure perform . Patients Chronic Blastic Phases ; Previously treat Flumatinib ; Previously document T315I mutation ; Previous therapy within protocol define timeframe , include : hydroxyurea within 24 hr , Imatinib Nilotinib Dasatinib within 28 day ) Cardiac dysfunction ; History congenital acquire bleed disorder unrelated CML ; Central nervous system leukemia ; Previous malignancy except CML ; Acute chronic liver severe kidney disease unrelated CML ; Pregnant , breastfeeding , child bear potential fail take effective contraception .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2015</verification_date>
</DOC>